Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC.CNCE · Entity 115906 | General Counsel | March 31, 2018 | April 13, 2018 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Legal Officer | July 27, 2020 | July 29, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONCERT PHARMACEUTICALS, INC.
Report date March 31, 2018 · Filed April 13, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,818 |
Reported balance
After 2018-03-31 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-03-31 · Tax withholding · Disposed 3,682 · Balance 33,818 F1: Transaction represents withholding of shares to satisfy tax withholding obligations upon the vesting of restricted stock units. F2: This amendment is being filed to reduce the number of securities beneficially owned by the reporting person by 12,500 shares of common stock due to the failure to achieve certain performance criteria set forth in the restricted stock unit grant agreement with the reporting person dated July 6, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction represents withholding of shares to satisfy tax withholding obligations upon the vesting of restricted stock units.
F2: This amendment is being filed to reduce the number of securities beneficially owned by the reporting person by 12,500 shares of common stock due to the failure to achieve certain performance criteria set forth in the restricted stock unit grant agreement with the reporting person dated July 6, 2017.
Solid Biosciences Inc.
Report date July 27, 2020 · Filed July 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,859 |
Ending reported balance
After 2020-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-07-27 · Exercise / conversion · Acquired 16,000 · Balance 166,000 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2020-07-28 · Sale · Disposed 5,141 · Balance 160,859 F2: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,000 |
Reported balance
After 2020-07-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-27 · Exercise / conversion · Disposed 16,000 · Balance 16,000 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: On January 27, 2020, the reporting person was granted 32,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units.
F3: On January 27, 2020, the reporting person was granted 32,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2020 Filed Jul 29, 2020 17:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 5,141 | $2.42 | $12,437.62 |
DisclosureSEC source: 0001209191-20-043952 · doc4.xml · nonDerivative · entry 2 HERSCHA LYNETTE · CIK 0001708198 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,859 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 17:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043952 · doc4.xml · derivative · entry 3 HERSCHA LYNETTE · CIK 0001708198 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 32,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 32,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 17:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 16,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043952 · doc4.xml · nonDerivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 18:01 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037688 · doc4.xml · nonDerivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: The reported transaction is a grant of restricted stock units representing 75,000 shares of common stock. This grant will vest in two equal installments with the first fifty percent vesting on March 11, 2021 and the second fifty percent on March 11, 2022. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 16:36 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018883 · doc4.xml · nonDerivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · shares: The reported transaction is a grant of restricted stock units representing 75,000 shares of common stock. This grant will vest evenly over 2 years with the first fifty percent vesting on the first anniversary of the grant date and the second fifty percent vesting on the second anniversary of the grant date. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 17:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Unit · Derivative | 32,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005408 · doc4.xml · derivative · entry 2 HERSCHA LYNETTE · CIK 0001708198 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2030-01-27 F2 · derivative.exercise_date: The restricted stock units will vest in 2 installments. Fifty percent will vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date and will vest automatically as to 100% of the unvested portion of such restricted stock unit grant upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 17:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-20-005408 · doc4.xml · derivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2020 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 16:06 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0000899243-19-004375 · doc4.xml · derivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · See Remark 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: This option was granted February 19, 2019 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 16:18 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Tax withholdingCommon Stock | 3,682 | $22.90 | $84,317.80 |
DisclosureSEC source: 0001209191-18-022920 · doc4.xml · nonDerivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,318 F1 · shares: Transaction represents withholding of shares to satisfy tax withholding obligations upon the vesting of restricted stock units. Read SEC document |
| March 31, 2018 Filed Apr 13, 2018 16:50 UTC Amendment | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Tax withholdingCommon Stock | 3,682 | $22.90 | $84,317.80 |
DisclosureSEC source: 0001209191-18-024843 · doc4a.xml · nonDerivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,818 F1 · shares: Transaction represents withholding of shares to satisfy tax withholding obligations upon the vesting of restricted stock units. F2 · balance_after: This amendment is being filed to reduce the number of securities beneficially owned by the reporting person by 12,500 shares of common stock due to the failure to achieve certain performance criteria set forth in the restricted stock unit grant agreement with the reporting person dated July 6, 2017. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 18:34 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantEmployee Stock Option (right to buy) · Derivative | 49,500 | $0.00 Strike: $27.59 | $0.00 |
DisclosureSEC source: 0001209191-18-002787 · doc4.xml · derivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 Underlying: Common Stock · 49,500 shares Expires 2028-01-03 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning on April 4, 2018. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 07:07 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-044472 · doc4.xml · nonDerivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: 50% of the RSUs granted to Ms. Herscha are eligible to vest on March 31, 2018, subject to the achievement certain performance criteria prior to March 31, 2018, including the closing of the Asset Purchase Agreement with Vertex Pharmaceuticals, Inc. and the institution by the Patent Trial and Appeal Board of a Post Grant Review petition filed by the Issuer against Incyte Corporation, and the remaining 50% of the RSUs are time-based awards and will vest on March 31, 2019. The number above represents the maximum number of shares that may be delivered pursuant to the award. F3 · price: Not applicable. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 07:36 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001209191-17-040711 · doc4.xml · derivative · entry 1 HERSCHA LYNETTE · CIK 0001708198 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning on September 15, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.